Clinical Advances in Hematology and Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Highlights in chronic lymphocytic leukemia from the 65th ASH Annual Meeting and Exposition: commentary
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 2(1):11-13.NO ABSTRACTPMID:38625034 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 16, 2024 Category: Cancer & Oncology Authors: Matthew S Davids Source Type: research

Thrombotic complications of influenza and COVID-19 infections
Clin Adv Hematol Oncol. 2024 Apr;22(3):106-107.NO ABSTRACTPMID:38588268 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Patricia K Nguyen Source Type: research

Highlights in prostate cancer from the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
Clin Adv Hematol Oncol. 2024 Apr;22(3):112-113.NO ABSTRACTPMID:38588269 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 8, 2024 Category: Cancer & Oncology Source Type: research

Six-year update of the ELEVATE-TN study on acalabrutinib
Clin Adv Hematol Oncol. 2024 Apr;22(3):121-122.NO ABSTRACTPMID:38588270 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Jeff Sharman Source Type: research

Coordination between the FDA and the US Patent and Trademark Office
Clin Adv Hematol Oncol. 2024 Apr;22(3):126-128.NO ABSTRACTPMID:38588271 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Kathi Vidal Source Type: research

Immunotherapy in the treatment of advanced or recurrent endometrial cancer
Clin Adv Hematol Oncol. 2024 Apr;22(3):129-139.ABSTRACTThe standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune ...
Source: Clinical Advances in Hematology and Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Juan Francisco Grau-Bejar Lorena Farinas-Madrid Carmen Garc ía-Duran David Garc ía-Illescas Roberta Mazzeo Ana Oaknin Source Type: research

The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors
Clin Adv Hematol Oncol. 2024 Apr;22(3):140-147.ABSTRACTDespite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity. These toxicities result from off-target effects of covalent BTK inhibitors and frequently lead to dose reductions and discontinuations of the drug. Noncovalent BTK inhibitors bind BTK in a unique fashion and, to date, have demonstrated an excellent safety profile as well as efficacy against a variety of B-cell malignanc...
Source: Clinical Advances in Hematology and Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Fateeha Furqan Nirav N Shah Source Type: research